(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss - 2Spanish bishops and government sign deal for compensation of church sexual abuse victims
- 3December’s full moon is the last supermoon of the year. Here’s what to know
- 4The Ascent of the Kona SUV: How Hyundai's Reduced Hybrid Is Vanquishing the Streets
- 5Defeating An inability to embrace success in Scholarly world: Individual Victories
- Figure out How to Augment Your Rooftop Substitution Speculation
- 10 times the sky amazed us in 2025
- Spotify Wrapped and Apple Music Replay are here: Top songs, albums and artists of 2025
- SUVs Known for Their Looks As opposed to Their Capacity
- Here are 10 stores where you can get a free Thanksgiving turkey
- Instructions to Upgrade the Security Elements of Your Kona SUV
- Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
- 'Yellowstone' made him a fan favorite. His biggest role isn't the one you see.
- CDC changes kids' vaccine schedule, removing universal recommendation for some shots
